ArticleThe American journal of case reports2025
SMARCA4-Deficient Undifferentiated Carcinoma: A Report of 2 Cases.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case report of SMARCA4-deficient undifferentiated gastric carcinoma diagnosed by endoscopic ultrasound-guided fine needle aspiration.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND SMARCA4-deficient undifferentiated carcinoma (SMARCA4-DUC) is a rare and aggressive malignancy caused by inactivation of the SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 4) gene, a critical component of the SWI/SNF chromatin-remodeling complex. Initially identified in thoracic tumors, it is increasingly recognized in extrathoracic sites, including the gastrointestinal tract. These tumors often mimic other malignancies, such as poorly differentiated adenocarcinomas, malignant melanoma, hematolymphoid malignancies, or sarcomas, complicating diagnosis. Histologically, SMARCA4-DUC shows expression loss of BRG1 (the protein encoded by SMARCA4) on immunohistochemistry (IHC). SMARCA4-DUC exhibits rapid progression, local invasion, and poor prognosis due to its undifferentiated morphology and high proliferative capacity. CASE REPORT Case 1 was a 71-year-old woman with a 13.6-cm gastric tumor involving GE junction, with direct invasion to pancreas and transverse mesocolon. Initial impression suggested gastrointestinal stromal tumor (GIST) of stomach or sarcoma. Endoscopic biopsy followed by targeted next-generation sequencing revealed a pathogenic SMARCA4 mutation. After confirming SMARCA4-DUC, she underwent extensive open surgery followed by postoperative adjuvant paclitaxel-carboplatin chemotherapy. She developed recurrence and was transferred to hospice care. Case 2 was an 80-year-old man with a 9.0-cm gastric tumor at cardia, directly invading the pancreas. Endoscopic biopsy revealed poorly differentiated tubular adenocarcinoma. Following laparoscopic gastrectomy, the specimen showed a predominantly undifferentiated malignant tumor with focal adenocarcinoma components. IHC demonstrated loss of BRG1 expression in the undifferentiated tumor component, confirming SMARCA4-DUC. He completed several cycles of adjuvant XELOX, without recurrence. CONCLUSIONS These 2 cases of SMARCA4-DUC of the stomach underscore the importance of molecular diagnostics and multidisciplinary management to avoid delayed diagnosis and to establish appropriate therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.